System-Specific Biopharmaceuticals

Kissei Pharmaceutical Co., Ltd.

Chugai Recommends Halting Tavneos Prescriptions Amid FDA Warnings and Data Manipulation Allegations

4547

Kissei Pharmaceutical's recent earnings appear solid, but concerns arise from a significant contribution of JP¥18b from unusual items, which may mislead investors about its underlying profitability. Despite a 45% growth in earnings per share over three years, analysts caution that statutory profits may not accurately reflect the company's true earnings power. Additionally, there are two warning signs to consider regarding the company's risks.

Simplywall

Kissei Pharmaceutical's (TSE:4547) Solid Earnings May Rest On Weak Foundations

AMGN

Amgen's Japanese partner, Kissei Pharmaceutical, has advised doctors to avoid prescribing Tavneos to new patients due to safety concerns following FDA warnings about liver injuries. Kissei is urging a reassessment of current patients' treatment amid scrutiny over trial data integrity. The FDA proposed withdrawing Tavneos' approval, citing manipulated data in clinical trials. Kissei is coordinating with Japanese health authorities to ensure patient safety while the drug remains approved in Japan.

benzinga_article

Amgen

Nichi-Iko Pharmaceutical Co., Ltd.

Churchill Capital XI

Amgen Japanese Partner Urges Caution On Tavneos Use

BRK.A

SBUX

BRK.B

MSFU

MSFL

MSFX

SpaceX plans to go public on June 12, potentially marking the largest IPO ever. Anthropic is raising $30 billion as AI companies attract significant VC funding. Kissei Pharmaceutical warned against prescribing a drug linked to 20 deaths in Japan. Berkshire Hathaway increased stakes in Delta and Macy's while exiting positions in several major companies. Starbucks is laying off 300 employees as part of a turnaround strategy. Bill Ackman is investing in Microsoft, citing its AI potential.

- SpaceX plans to go public on June 12, with its IPO expected to be the largest ever.  
- Anthropic is raising $30 billion in venture capital as a leading AI company captures significant funding this year.  
- Kissei Pharmaceutical has advised doctors in Japan to cease prescribing an immune disease drug after 20 patients died.

MorningStar

Berkshire Hathaway

Starbucks

Macys

Berkshire Hathaway B

Delta Air Lines

Direxion Daily MSFT Bull 2X Shares

GraniteShares 2x Long MSFT Daily ETF

T-Rex 2X Long Microsoft Daily Target ETF

Amazon

Mastercard

Visa

Unitedhealth

Deere

Microsoft

NVIDIA

Toyota Motor

Toyota Motor Corp.

Stellantis NV

DONGFENG GROUP

Honda Motor Co., Ltd.

Honda Motor

NVIDIA Corporation

Toyota

Dow Jones Top Company Headlines at 5 PM ET: SpaceX Is Aiming to Go Public on June 12 in What Stands to Be Biggest IPO Ever | Anthropic ...

Kissei Pharmaceutical (TSE:4547) reported FY 2026 Q4 revenue of ¥24.8b and Basic EPS of ¥66.70, with trailing twelve month revenue at ¥97.4b and EPS at ¥331.53. A one-off gain of ¥18.4b boosted margins to 14.1%. Despite a 15.2% earnings growth, analysts caution about sustainability due to this gain. The stock trades at a trailing P/E of 13.1x, below the industry average, with a DCF fair value of ¥5,953.51 suggesting upside potential. However, forecast growth is slower than the broader market, raising concerns about future performance.

Kissei Pharmaceutical (TSE:4547) One Off Gain Lifts Margin And Tests Bullish Earnings Narrative

Kissei Pharmaceutical reported a fiscal 2026 net sales increase of 10.3% to ¥97.4 billion but faced an operating loss of ¥2.9 billion. Despite this, profit attributable to owners rose 15.2% to ¥13.8 billion. The company raised its annual dividend to ¥160 per share and forecasts a recovery to ¥4.4 billion in operating profit for the year ending March 2027, with projected net income of ¥14.5 billion. Analysts rate the stock as a Buy with a price target of ¥5400.00.

Tip Ranks

Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery

Jefferies analyst Miyabi Yamakita has maintained a Buy rating for Kissei Pharmaceutical Co (KSPHF) with a price target of Yen5,400.00, while the shares closed at Yen4,320.00. The analyst has a 1.6% average return and a 48.48% success rate, focusing on the Healthcare sector. The consensus rating for Kissei is a Moderate Buy, with an average price target of Yen5,499.13.

Jefferies Financial

Medipal Holdings Corporation

SanBio Co., Ltd.

Jefferies Sticks to Their Buy Rating for Kissei Pharmaceutical Co (KSPHF)

Kissei Launches Yselty in Japan, Expanding Global Uterine Fibroid Treatment Portfolio